CLARITY PHARMACEUTICALS LTD

8.64%

$2.22

Market Cap $713.4M

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

CU6

CU6 - ASX Charts

36 37 38

15:36

2.2K

871K

15:36

Last post

slick

2.2K

871K

CU6

Broker Consensus

15:00

20K

15:00

Last post mazza28

20K

CU6

CU6 - Media and Industry News

17 18 19

07:57

1.1K

494K

07:57

Last post cpt_yossarian

1.1K

494K

CU6

CU6 - General discussion

7 8 9

03/05/25

497

203K

03/05/25

Last post cpt_yossarian

497

203K

CU6

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

02/05/25

10K

02/05/25

Last post bedger

10K

CU6

Ann: Change in substantial holding

02/05/25

973

02/05/25

Last post

ASX News

973

CU6

Ann: Change in substantial holding

22/04/25

689

22/04/25

Last post

ASX News

689

CU6

Ann: Clarity to present COBRA and CLARIFY abstracts

22/04/25

104

41K

22/04/25

Last post ttppxx

104

41K

See All Discussions

Timeline

Change in substantial holding
02 May 08:26	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 15:06	Share

Change in substantial holding
22 Apr 18:51	Share

Ceasing to be a substantial holder
17 Apr 16:33	Share

Clarity signs commercial-scale copper-64 Supply Agreement
17 Apr 09:55	Share

$11.1 million RDTI and refocus on high-priority programs
17 Apr 09:53	Share

Becoming a substantial holder
16 Apr 15:43	Share

First patient treated in the Phase II of the SECuRE trial
15 Apr 09:40	Share

Change of Registered Office and Registry Address
14 Apr 10:01	Share

Becoming a substantial holder
11 Apr 08:21	Share

Notification of cessation of securities - CU6
10 Apr 17:18	Share

Becoming a substantial holder
09 Apr 18:26	Share

Cleansing Notice
05 Mar 13:57	Share

Application for quotation of securities - CU6
05 Mar 13:51	Share

Clarity signs Cu-64 Supply Agreement with UQ
05 Mar 09:57	Share

SECuRE trial update
05 Mar 09:55	Share

Half Yearly Report and Accounts
28 Feb 15:52	Share

Appendix 4D
28 Feb 15:52	Share

Clarity receives US FDA FTD for the treatment of mCRPC
19 Feb 09:31	Share

Response to ASX Cleansing Notice Timing Letter
18 Feb 11:04	Share

Cleansing Notice
11 Feb 14:00	Share

Application for quotation of securities - CU6
11 Feb 13:53	Share

Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
11 Feb 09:40	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 11:57	Share

Cleansing Notice
29 Jan 18:54	Share

Application for quotation of securities - CU6
29 Jan 18:48	Share

Clarity to present COBRA and CLARIFY abstracts
28 Jan 09:37	Share

Clarity receives U.S. FDA Fast Track Designation
24 Jan 09:40	Share

Cleansing Notice
22 Jan 15:46	Share

Application for quotation of securities - CU6
22 Jan 15:41	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.22		Change -0.210(8.64%)		Mkt cap ! $713.4M

Open	High	Low	Value	Volume
$2.32	$2.38	$2.18	$6.417M	2.845M

Buyers (Bids)

No.	Vol.	Price($)
1	10000	$2.21

Sellers (Offers)

Price($)	Vol.	No.
$2.22	39670	5

View Market Depth

No.	Vol.	Price($)
1	10000	2.210
1	2500	2.200
7	21781	2.190
4	11045	2.180
3	61417	2.170

Price($)	Vol.	No.
2.220	39670	5
2.230	34108	6
2.240	17880	3
2.250	28711	2
2.260	8123	1

Last trade - 16.10pm 12/05/2025 (20 minute delay)


Last $2.21		Change -0.210 ( 8.53 %)
Open	High	Low	Volume
$2.37	$2.38	$2.18	594888
Last updated 15.59pm 12/05/2025 ?

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD

Latest Threads

Lincoln Mine Acquisition: High Grade, Permitted, Near Production

Timeline

Featured News

Latest Videos

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

10 Aug 2023 12:13 (AEST)

Latest Articles

Clarity scribes deal on delivery of copper 64 isotopes

Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano to deliver Cu-64 isotopes

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning could offer crucial moral support.For those patients (who have also already received first-stage less ...

Clarity jumps as FDA awards fast track status for PET scan imaging agent

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen ...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News